Secure Translational Funding
The Translational Research Office (TRO) manage a number of devolved funding streams targeting early stage proof-of-concept projects and have extensive knowledge of the UK translational funding landscape. We can help source the most appropriate funding scheme for projects and ensure that the most compelling cases for support are generated. Securing funding enables projects to progress along the translational path, de-risking future investment.
KEY ACTIVITIES
The TRO administrate translational proof-of-concept funding through the Medical and Life Sciences Translation Fund (MLSTF). The fund is open to all University of Oxford researchers and provides consolidated internal proof of concept funding for translational medical and life sciences projects.
The TRO also identify the most appropriate external grant funding source for a project. A few of the translational research funding schemes available to researchers are:
|
Award |
Application deadline(s) |
Award volume and duration |
Comments |
|
Experimental Medicine Award by Cancer Research UK
|
Preliminary Submission 4th April 2022 |
£1–5M |
The Experimental Medicine Award funds highly ambitious translational research conducted in association with a clinical trial or well-designed clinical study in the field of oncology. Translational research considered within the scheme must be associated with one or more clinical trials or clinical studies within the lifetime of the award, where it can be clearly demonstrated that the findings would directly impact on the conduct of the trial(s)/studies. Associated trial(s)/studies may be funded as part of an Experimental Medicine Award. |
|
MRC Developmental Pathway Funding Scheme (DPFS) |
Stage 1 (Outline): 20th of March 2024
Stage 2: By invitation only after shortlisting |
Award Volume: There is no limit to the amount of funding you can apply for. You should justify the resources needed in the context of the proposed work. Duration: There is no limit to the duration of your project. You should justify the timescale of the project in the context of the proposed work.
|
This scheme aims to drive fundamental discoveries stemming from MRC’s research boards and the wider academic community along the developmental pathway towards patient benefit and or commercialisation. |
|
|
Call not currently open |
8 weeks |
8 weeks part-time, online programme helping early-stage research teams to make the first steps into market discovery. |
|
|
Call not currently open |
£35k 12 weeks |
Up to £35k to ‘get out of the lab’ and validate commercially promising ideas in the marketplace, over 12 week period. |
|
|
Deadline for outline stage: 13 December 2023 and 19 June 2024 Full-stage applications by invite only. |
£750k 3 years |
Up to £750k for projects lasting up to three years that address an unmet healthcare need in heart and circulatory disease. |
|
Therapeutic Catalyst - Cancer Research UK
|
Open until awarded. |
£250k 18 months |
Up to £250k for projects lasting up to 18 months. Drug discovery proposals, including, but not limited to: - Deconvolution and validation of novel targets and pathways with clear therapeutic potential - Novel therapeutic approaches to validated targets - Development of platforms, assays and screens to identify novel cancer therapeutics or targets. |
The TRO supports developing robust project plans and compelling applications for funding. Our Translational Research Managers can support grant writing activities, provide project management support and advise on long-term translational research strategies.
The TRO works closely with Oxford University Innovation (OUI), the Medical Sciences Business Partnerships Office (BPO) and University of Oxford's Research Services (RS) to ensure appropriate expertise and advice is sought at key stages in project development.